OncoMatch/Clinical Trials/NCT07751380
Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma
Is NCT07751380 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies Biological/Vaccine: hBRCA84D CAR T cells for sarcoma.
Treatment: Biological/Vaccine: hBRCA84D CAR T cells — MIGHTY is a multicentre, open label, phase 1 clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children, teenagers and young adults aged 1-24 with relapsed or refractory (r/r) rhabdomyosarcoma (RMS), Ewing sarcoma (ES) or desmoplastic small round cell tumour (DSRCT). The study will assess the feasibility of generating the ATIMP and administering hBRCA84D CAR T cells to patients with r/r RMS, ES or DSRCT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Biomarker criteria
Required: CD276 expression
Demographics
Prior therapy
Must have received: systemic therapy
Relapsed or refractory disease after one or multiple lines of previous treatment.
Cannot have received: gene therapy
Prior treatment with investigational or approved gene therapy or cell therapy products.
Cannot have received: cell therapy
Prior treatment with investigational or approved gene therapy or cell therapy products.
Lab requirements
Blood counts
Absolute lymphocyte count ≥ 0.25 x 10^9/L.
Kidney function
Creatinine ≤1.5 x ULN for age, if higher, an estimated (calculated) creatinine clearance must be ≥ 60 ml/min/1.73 m2.
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%
Creatinine ≤1.5 x ULN for age, if higher, an estimated (calculated) creatinine clearance must be ≥ 60 ml/min/1.73 m2. Left ventricular ejection fraction (LVEF) ≥ 50%. Absolute lymphocyte count ≥ 0.25 x 10^9/L.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07751380 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy, cell therapy disqualifies patients from enrollment.
Does this trial require CD276?
Yes, CD276 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 24 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages